Drugs / Th1/Tc1 Rapa Cell Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01239368 | Nov 2010 → Aug 2017 | plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Th1/Tc1 Rapa Cell Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01239368 ↗ |
| Known as | Th1/Tc1.Rapa cells | “ex vivo rapamycin-generated, anti-cluster of differentiation 3 (CD3) and anti-cluster of differentiation 28 (CD28) co-stimulated, Th1/Tc1 lymphocytes (Th1/Tc1.Rapa cells)” NCT01239368 ↗ |
| Modality | Cell therapy | “modified primary human T cells” NCT01239368 ↗ |